Historical Valuation
X T L Biopharmaceuticals Ltd (XTLB) is now in the Fair zone, suggesting that its current forward PE ratio of 1.20 is considered Fairly compared with the five-year average of 5.94. The fair price of X T L Biopharmaceuticals Ltd (XTLB) is between 0.60 to 4.84 according to relative valuation methord.
Relative Value
Fair Zone
0.60-4.84
Current Price：0.67
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
X T L Biopharmaceuticals Ltd (XTLB) has a current Price-to-Book (P/B) ratio of -11311.32. Compared to its 3-year average P/B ratio of -420.35 , the current P/B ratio is approximately 2590.94% higher. Relative to its 5-year average P/B ratio of -96.55, the current P/B ratio is about 11615.47% higher. X T L Biopharmaceuticals Ltd (XTLB) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -4.78%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -4.37% , the current FCF yield is about -100.00% lower.
P/B
Median3y
-420.35
Median5y
-96.55
FCF Yield
Median3y
-4.78
Median5y
-4.37
Competitors Valuation Multiple
AI Analysis for XTLB
The average P/S ratio for XTLB competitors is 16.10, providing a benchmark for relative valuation. X T L Biopharmaceuticals Ltd Corp (XTLB.O) exhibits a P/S ratio of 0.02, which is -99.88% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
AI Analysis for XTLB
1Y
3Y
5Y
Market capitalization of XTLB increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of XTLB in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is XTLB currently overvalued or undervalued?
X T L Biopharmaceuticals Ltd (XTLB) is now in the Fair zone, suggesting that its current forward PE ratio of 1.20 is considered Fairly compared with the five-year average of 5.94. The fair price of X T L Biopharmaceuticals Ltd (XTLB) is between 0.60 to 4.84 according to relative valuation methord.
What is X T L Biopharmaceuticals Ltd (XTLB) fair value?
XTLB's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of X T L Biopharmaceuticals Ltd (XTLB) is between 0.60 to 4.84 according to relative valuation methord.
How does XTLB's valuation metrics compare to the industry average?
The average P/S ratio for XTLB's competitors is 16.10, providing a benchmark for relative valuation. X T L Biopharmaceuticals Ltd Corp (XTLB) exhibits a P/S ratio of 0.02, which is -99.88% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for X T L Biopharmaceuticals Ltd (XTLB) as of Jan 10 2026?
As of Jan 10 2026, X T L Biopharmaceuticals Ltd (XTLB) has a P/B ratio of -11311.32. This indicates that the market values XTLB at -11311.32 times its book value.
What is the current FCF Yield for X T L Biopharmaceuticals Ltd (XTLB) as of Jan 10 2026?
As of Jan 10 2026, X T L Biopharmaceuticals Ltd (XTLB) has a FCF Yield of 0.00%. This means that for every dollar of X T L Biopharmaceuticals Ltd’s market capitalization, the company generates 0.00 cents in free cash flow.
What is the current Forward P/E ratio for X T L Biopharmaceuticals Ltd (XTLB) as of Jan 10 2026?
As of Jan 10 2026, X T L Biopharmaceuticals Ltd (XTLB) has a Forward P/E ratio of 1.20. This means the market is willing to pay $1.20 for every dollar of X T L Biopharmaceuticals Ltd’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for X T L Biopharmaceuticals Ltd (XTLB) as of Jan 10 2026?
As of Jan 10 2026, X T L Biopharmaceuticals Ltd (XTLB) has a Forward P/S ratio of 0.02. This means the market is valuing XTLB at $0.02 for every dollar of expected revenue over the next 12 months.